B-Blocker Pharmacogenetics in Heart Failure

摘要

Polymorphisms in the beta-1 adrenergic receptor that (1) affect tolerability to beta-blocker treatment or (2) influence responsiveness to beta-blocker treatment are disclosed. Additionally, methods of predicting that an individual would obtain clinical improvement in left ventricular function as a result of beta-blocker therapy or identifying at least one individual that would obtain a clinical improvement in left ventricular function as a result of beta-blocker therapy are provided. Methods of treating patients characterized by such polymorphisms are also illustrated.